Massachusetts Financial Services Co. MA Has $16.88 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Massachusetts Financial Services Co. MA decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 419,490 shares of the company’s stock after selling 33,887 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Kymera Therapeutics were worth $16,876,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after acquiring an additional 95,547 shares in the last quarter. HighTower Advisors LLC acquired a new stake in Kymera Therapeutics during the third quarter worth approximately $494,000. Charles Schwab Investment Management Inc. increased its holdings in Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company’s stock worth $15,577,000 after purchasing an additional 20,346 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Kymera Therapeutics by 174.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,899 shares of the company’s stock valued at $801,000 after buying an additional 12,643 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after buying an additional 308,954 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. HC Wainwright lifted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Citigroup started coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company. BTIG Research started coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Stephens restated an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Stock Down 6.8 %

KYMR stock opened at $22.07 on Monday. The firm has a market capitalization of $1.43 billion, a PE ratio of -9.43 and a beta of 2.22. Kymera Therapeutics, Inc. has a twelve month low of $21.40 and a twelve month high of $53.27. The stock’s 50 day moving average is $34.02 and its 200-day moving average is $40.99.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock valued at $324,567 over the last ninety days. Corporate insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.